Clinical Trial Update: A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

Open-label Phase 3 study assessing the long-term safety of difamilast 1% ointment in mild-to-moderate atopic dermatitis; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Difamilast Ointment 1% (Difamilast)

Snippet

Sponsor: Acrotech Biopharma Inc. | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED